Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

info@grandmedicalgroup.ch

+41 415880810

Each vial contains 0.5 g or 1g ceftriaxone, powder for solution for injection in vial No 1 with 3.5 ml solvent in ampoule No 1

PHARMACOLOGIC PROPERTIES

ATC code: J01DD04, Antibacterials for systemic use, third-generation cephalosporins. Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. Ceftriaxone and other third-generation antibiotics are used to treat organisms that tend to be resistant to many other antibiotics.

THERAPEUTIC INDICATIONS

Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth):
• Bacterial Meningitis,
• Community acquired pneumonia,
• Hospital acquired pneumonia,
• Acute otitis media,
• Intra-abdominal infections,
• Complicated urinary tract infections (including pyelonephritis),
• Infections of bones and joints,
• Complicated skin and soft tissue infections,
• Lyme disease,
• Gonorrhea,
• Syphilis,
• Bacterial endocarditis,
• Acute exacerbations of chronic obstructive pulmonary disease in adults, • For pre-operative prophylaxis of surgical site infections,
• In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.